Immune-Related Adverse Events Mimicking Behcet&apos;s Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Anti-programmed cell death 1(anti-PD-1) antibodies are immune checkpoint inhibitors (ICIs) used as a treatment option for a number of cancers to expand lifespan. However, the toxicity caused by ICIs is often unpredictable and can be occasionally life-threatening.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Iran J Immunol

Title: Iranian journal of immunology : IJI

Publisher:

ISSN (Electronic): 1735-367X

ISSN (Print): 1735-1383

Publication date (Electronic): Jun 2020

Volume: 17

Issue: 2

Affiliations

[1 ] Department of Surgery,The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.

Article

Publisher Item ID: 07

DOI: 10.22034/iji.2020.85507.1717

PubMed ID: 32602470

SO-VID: 58aa7e97-1011-4a96-930c-e4db6c38bf20

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
Authors: Peng Yang, Xiao Zhou, Xuefeng Yang …

See all cited by

Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.

Read this article at